| 41.19 Delayed Data As of Aug 23 |  +0.21 / +0.51%Today’s Change | 36.41 Today|||52-Week Range 42.47 | +7.80% Year-to-Date |
| Top Analyst Reports for U.S. Bancorp, Duke Energy & Glaxo Aug 23 / Zacks.com - Paid Partner Content | Better Buy: Eli Lilly vs. GlaxoSmithKline Aug 18 / MotleyFool.com - Paid Partner Content |
| Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit Aug 23 / Zacks.com - Paid Partner Content | Ionis Pharmaceuticals Looks to Partners to Pay the Bills Aug 14 / MotleyFool.com - Paid Partner Content |
| Glaxo Submits First Regulatory Application for Daprodustat Aug 22 / Zacks.com - Paid Partner Content | Should Value Investors Consider GlaxoSmithKline (GSK) Stock? Aug 13 / Zacks.com - Paid Partner Content |
| Previous close | 40.98 |
| Today’s open | 41.42 |
| Day’s range | 41.07 - 41.73 |
| Volume | 3,375,531 |
| Average volume (3 months) | 2,402,858 |
| Market cap | $102.8B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -7.35% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 18.9 |
| Price/Sales | 2.31 |
| Price/Book | 18.26 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | -2.10 | -1.88% |
| SNYSanofi | +0.01 | +0.02% |
| ABBVAbbVie | -1.55 | -2.30% |
| NVONovo Nordisk | -0.43 | -0.82% |
| Next reporting date | October 23, 2019 |
| EPS forecast (this quarter) | $0.78 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Iain James Mackay |
Corporate headquarters Brentford, Greater London |
